A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now.

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed semaglutide had a 50% higher risk of being diagnosed with a hair-loss condition compared to those prescribed Contrave. That risk was twice as high for women as for men.